T-Cell Mediated Response after Primary and Booster SARS-CoV-2 Messenger RNA Vaccination in Nursing Home Residents
暂无分享,去创建一个
A. Sciarretta | A. Palamara | G. Fedele | R. Incalzi | P. Stefanelli | P. Leone | A. Malara | L. Spinelli | A. Di Lonardo | E. Olivetta | A. Palmieri | A. Mazzoli | F. Berardi | I. Schiavoni | M. Stefanelli | C. Cafariello | Deborah Spaccaferro | R. Ursino | Riccardo Bernardi | G. Onder | V. Leccese | Lucia Amici | Lucia Francesca Riccardo Mario Anila Ida Claudia Serena Amici Berardi Bernardi Cardillo Cobani Conf | M. Cardillo | Anila Cobani | Ida Confessore | Claudia Fiorucci | S. Guerriero | Liudmila Kountsevitch | F. Ruocco | P. Sabino | Romina Viotti | Roberta Granata | Roberta Granata
[1] A. Copas,et al. Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of long-term care facilities: an observational cohort study , 2022, The Lancet Healthy Longevity.
[2] P. Rieu,et al. Immune Responses after a Third Dose of mRNA Vaccine Differ in Virus-Naive versus SARS-CoV-2– Recovered Dialysis Patients , 2022, Clinical journal of the American Society of Nephrology : CJASN.
[3] G. Onder,et al. A Third Dose of mRNA COVID-19 Vaccine Significantly Enhances Anti–SARS-CoV-2 Spike IgG Response in Nursing Home Residents in Italy , 2022, Journal of the American Medical Directors Association.
[4] A. Benetos,et al. Anti‐spike IgG antibody kinetics following the second and third doses of BNT162b2 vaccine in nursing home residents , 2022, Journal of the American Geriatrics Society.
[5] E. Albert,et al. SARS-CoV-2 adaptive immunity in nursing home residents following a third dose of the Comirnaty® COVID-19 vaccine , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] B. Ramos,et al. Humoral and Cellular Response after mRNA Vaccination in Nursing Homes: Influence of Age and of History of COVID-19 , 2022, Vaccines.
[7] M. Picot,et al. Strong Decay of SARS-CoV-2 Spike Antibodies after 2 BNT162b2 Vaccine Doses and High Antibody Response to a Third Dose in Nursing Home Residents , 2022, Journal of the American Medical Directors Association.
[8] G. Onder,et al. Monitoring COVID-19 vaccine use in Italian long term care centers: The GeroCovid VAX study , 2022, Vaccine.
[9] G. Brady,et al. Previous SARS-CoV-2 Infection, Age, and Frailty Are Associated With 6-Month Vaccine-Induced Anti-Spike Antibody Titer in Nursing Home Residents , 2022, Journal of the American Medical Directors Association.
[10] Bärbel Camara,et al. Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults , 2021, Nature Microbiology.
[11] V. Lauschke,et al. Immunogenicity after 6 months of BNT162b2 vaccination in frail or disabled nursing home residents: The COVID‐A Study , 2021, Journal of the American Geriatrics Society.
[12] A. Duhamel,et al. Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People , 2021, Frontiers in Immunology.
[13] M. Stiffel,et al. COVID-19 in long-term care , 2021, OECD Health Working Papers.
[14] V. Ippolito,et al. Clinical Features of SARS-CoV-2 Infection in Italian Long-Term Care Facilities: GeroCovid LTCFs Observational Study , 2021, Journal of the American Medical Directors Association.
[15] H. Ikematsu,et al. Contrasting specific antibody response to BNT162b2 mRNA vaccination in SARS-CoV-2-naive and previously infected nursing home residents , 2021, Journal of Infection.
[16] Frances E. Muldoon,et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 , 2021, Nature.
[17] E. Albert,et al. B- and T-cell immune responses elicited by the Comirnaty® COVID-19 vaccine in nursing-home residents , 2021, Clinical Microbiology and Infection.
[18] M. Cameron,et al. Reduced BNT162b2 Messenger RNA Vaccine Response in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Naive Nursing Home Residents , 2021, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.
[19] M. Picot,et al. Antibody response after one and two jabs of the BNT162b2 vaccine in nursing home residents: The CONsort‐19 study , 2021, Allergy.
[20] G. Onder,et al. Proceedings from an International Virtual Townhall: Reflecting on the COVID-19 Pandemic: Themes from Long-Term Care , 2021, Journal of the American Medical Directors Association.
[21] G. Pawelec,et al. Unanticipated efficacy of SARS-CoV-2 vaccination in older adults , 2021, Immunity & ageing : I & A.
[22] D. Lauffenburger,et al. Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.
[23] L. Ferrucci,et al. The conundrum of human immune system “senescence” , 2020, Mechanisms of Ageing and Development.
[24] S. Sinha,et al. A Comparison of COVID-19 Mortality Rates Among Long-Term Care Residents in 12 OECD Countries , 2020, Journal of the American Medical Directors Association.
[25] M. Kivipelto,et al. Age, Frailty, and Comorbidity as Prognostic Factors for Short-Term Outcomes in Patients With Coronavirus Disease 2019 in Geriatric Care , 2020, Journal of the American Medical Directors Association.
[26] I. Bogoch,et al. Risk Factors Associated With Mortality Among Residents With Coronavirus Disease 2019 (COVID-19) in Long-term Care Facilities in Ontario, Canada , 2020, JAMA network open.
[27] Morten Nielsen,et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 , 2020, Cell.
[28] G. Onder,et al. Clinical Characteristics of Hospitalized Individuals Dying with COVID-19 by Age Group in Italy , 2020, The journals of gerontology. Series A, Biological sciences and medical sciences.
[29] D. Sinclair,et al. Why does COVID-19 disproportionately affect older people? , 2020, Aging.